Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
2022. augusztus 22., hétfő 12:00 |
LTS takes next step in its Growth Journey with the acquisition of Tapemark Inc. |
|
Andernach, Germany, 22 August, 2022 (APA/OTS) - LTS LOHMANN Therapie-Systeme AG ("LTS") announces the closing of the acquisition of Tapemark Inc. ("Tapemark") located in St. Paul, MN, USA. This acquisition combines Tapemark, a world-class CDMO specialized in transdermal drug delivery systems and oral thin films as well as unit dose semi-solid drug and iontophoresis products with LTS, a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"), Oral Thin Films ("OTF") and Micro Array Patches (MAP) for major Bio- /Pharmaceutical, Generic, and Consumer Health companies. |
With the acquisition, Tapemark´s St. Paul facility will become part
of the worldwide operations network of LTS, along with LTS' existing
facilities in Andernach, Germany and West Caldwell, NJ in the US.
Bas van Buijtenen, CEO of LTS, commented, "We are very pleased to
welcome the Tapemark team to the LTS family. This strategic
acquisition demonstrates our commitment to continue to set the
standard as the best CDMO in TTS and OTF and to strengthen our
footprint in the US, the world's most important pharma market. We
will offer an even more complete portfolio of drug delivery
expertise and expanded manufacturing capabilities to our customers
and their patients, and we are excited to welcome Tapemark's
customers to LTS' global network. The acquisition strengthens our
R&D capabilities in North America, allowing us to bring ever more
innovation and development support to players developing innovative
therapies and new drug delivery systems. With that, we're even
better positioned to address our customers' desire for a single
partner to support them from feasibility through commercialization.
We are particularly pleased that such a talented team is joining
our organization. I am delighted that Beau Garrett will be
strengthening our Global Leadership Team in the role of SVP Strategy
and Corporate Development. His track record as a leader successfully
driving growth will bolster our LTS Growth Journey."
Beau Garrett, CEO of Tapemark, noted, "Joining LTS strengthens our
ability to craft the best product development and manufacturing
strategy to deliver complex drugs for our customers who ultimately
bring these to market and help patients around the world. Having
spoken to our customers, I know they are excited to benefit from the
breadth of LTS's global technology portfolio, its product
development capabilities, and the vast global network. Together, we
will reach more pharmaceutical partners and ultimately help more
patients. Personally, I am pleased our executive team is joining
such a strong team at LTS. From the day I met Bas and several of the
senior leaders at LTS, I knew this was the right fit for both
companies, our employees, and our customers."
The transaction has obtained the necessary regulatory approvals and
has closed as of August 19, 2022. Financial details of the
transaction are not disclosed. Bourne Partners served as the
exclusive financial advisor to Tapemark.
About LTS:
LTS LOHMANN Therapie-Systeme AG is a leading pharmaceutical
technology company that develops and manufactures innovative drug
delivery systems such as Transdermal Patches ("TTS") and Oral Thin
Films ("OTF") for the pharmaceutical industry. LTS maintains its
leading position through the continuous refinement of its core TTS
and OTF technologies and by advancing emerging drug delivery
technologies, including Micro Array Patches (MAP) for the
transdermal delivery of large molecule, biological actives and
vaccines. Founded in 1984, LTS operates today from three sites: in
Andernach, Germany, West Caldwell, NJ, USA and St. Paul, MN, USA.
LTS has also a representative office in Shanghai, China.
Contact: Dr. Iris Schnitzler Phone: +49 (0) 2632 99 - 2589 E-mail: iris.schnitzler@ltslohmann.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|